Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

What's in the Cards for Enlivex (ENLV) This Earnings Season?

By Zacks Investment ResearchStock MarketsNov 03, 2020 01:44AM ET
www.investing.com/analysis/whats-in-the-cards-for-enlivex-enlv-this-earnings-season-200543361
What's in the Cards for Enlivex (ENLV) This Earnings Season?
By Zacks Investment Research   |  Nov 03, 2020 01:44AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Investors will focus on pipeline updates when Israel-based clinical-stage immunotherapy company, Enlivex Therapeutics (NASDAQ:ENLV), Ltd ENLV, reports results for the three months ending Sep 30, 2020.

In the last reported quarter, the company beat earnings estimates by 4.17%.

The company’s stock has surged 37.5% year to date against the industry’s decline of 10%.

Let’s see, how things are shaping up for this announcement.

Factors at Play

Enlivex Therapeutics is a clinical-stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing.

The main focus will be primarily on updates on the company’s innovative immunotherapy candidate, Allocetra. This is a novel immunotherapy candidate based on a unique mechanism of action that targets clinical indications such as preventing or treating complications associated with sepsis and acute multiple organ failure, bone marrow transplants and/or hematopoietic stem-cell transplants.

The company recently reported that the first two patients have been dosed in an investigator-initiated phase II clinical study evaluating Allocetra in severe and critical COVID-19 patients. This study is designed as a multi-center, investigator-initiated, phase II clinical study. The study is expected to recruit up to 24 COVID-19 patients in severe or critical conditions. It will evaluate Allocetra in combination with standard-of-care treatment. The study plans to evaluate safety, tolerability, cytokine profile and efficacy parameters. Each patient in the clinical study will be observed for 28 days following the administration of Allocetra. Additional updates on the same will be in focus.

Last month, the company reported positive top-line results from a phase Ib investigator-initiated clinical trial of Allocetra in COVID-19 patients in severe and critical condition. The phase Ib study took place in Hadassah Hospital, one of the largest hospitals in Israel, and included five COVID-19 patients, with three in severe condition and two in critical condition. All five patients completely recovered from their respective severe or critical condition and were released from the hospital after an average of 5 days (severe) and 9 days (critical) when they were all COVID-19 PCR negative, following the administration of Allocetra.

Meanwhile, research and development expenses and general and administrative expenses surged in the previous quarter and the trend has most likely continued in the to-be-reported quarter.

Earnings Whispers

Our proven model does not conclusively predict an earnings beat for the Enlivex this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of a positive surprise. But this is not the case here. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.

Earnings ESP: Enlivex has an Earnings ESP of 0.00%.

Zacks Rank: The company currently carries a Zacks Rank #3.

Stocks to Consider

Here are a few stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this season.

Geron (NASDAQ:GERN) GERN has an Earnings ESP of +6.25% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.

Regenxbio, Inc. RGNX has an Earnings ESP of +4.76% and a Zacks Rank #3.

Mylan (NASDAQ:MYL) MYL has an Earnings ESP of +1.69% and a Zacks Rank #3.

Legal Marijuana: An Investor’s Dream

Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.

Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.

Download Marijuana Moneymakers FREE >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Mylan N.V. (MYL): Free Stock Analysis Report

Geron Corporation (GERN): Free Stock Analysis Report

REGENXBIO Inc. (RGNX): Free Stock Analysis Report

Bio Blast Pharma Ltd. (ENLV): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research
What's in the Cards for Enlivex (ENLV) This Earnings Season?
 

Related Articles

What's in the Cards for Enlivex (ENLV) This Earnings Season?

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email